MedTrace Logo

Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment

NCT04530422 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2020-08-28

No results posted yet for this study

Summary

Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies.

This study aiming to evaluate the anti-HCV medications efficacy "Sofosbuvir-Ledipasvir" in treatment of moderate cases with SARS-COV-2 infection, in comparison to the standard treatment (hydroxychloroquine, oseltamivir and azithromycin).

Conditions

  • Covid19

Interventions

DRUG

Sofosbuvir plus Ledipasvir

Sofosbuvir plus Ledipasvir, once daily for 15 to 21days * Oseltamivir 150 mg q 12 hours for 10 days ; * HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and * Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.

Sponsors & Collaborators

  • Almaza Military Fever Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2020-07-08
Completion
2020-07-23

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530422 on ClinicalTrials.gov